2-iodo-3-(trifluoromethyl)benzonitrile | 905600-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-iodo-3-(trifluoromethyl)benzonitrile
• CAS: 905600-49-9
• 化学式: C₈H₃F₃IN
• 分子量: 297.018
• InChiKey: CGUFWPQURMBLMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE ET DE 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ORÉXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013068935A1

  公开（公告）日：2013-05-16

  The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的2-(1,2,3-三唑-2-基)苯甲酰胺和3-(1,2,3-三唑-2-基)吡啶甲酰胺衍生物，式(I)中Ar1、Q以及R1至R5如描述，它们的制备方法，它们的药用盐，以及它们作为药物的用途，含有式(I)的一个或多个化合物的药物组合物，特别是它们作为促进睡眠的受体拮抗剂的用途。
• 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150158855A1

  公开（公告）日：2015-06-11

  The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar 1 , Q, and R 1 to R 5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）中的2-(1,2,3-三唑-2-基)苯甲酰胺和3-(1,2,3-三唑-2-基)吡啶甲酰胺衍生物，其中Ar1、Q和R1至R5如描述所述，以及它们的制备方法，其药学上可接受的盐，以及它们作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠激素受体拮抗剂的用途。
• Use of selective P2X7 receptor antagonists
  申请人：Perez-Medrano Arturo

  公开号：US20060211739A1

  公开（公告）日：2006-09-21

  The present invention relates to the use of selective P2X 7 receptor antagonists of formula I, or a pharmaceutically acceptable salt or prodrug thereof wherein D, R 1 and R 2 are as defined in claim 1 , for the treatment of neuropathic pain, chronic inflammatory pain, inflammation, neurodegeneration and for promoting neuroregeneration,

  本发明涉及使用公式I中的选择性P2X7受体拮抗剂，或其药学上可接受的盐或前药，其中D、R1和R2如权利要求书1中定义的，用于治疗神经病理性疼痛、慢性炎性疼痛、炎症、神经退行性疾病以及促进神经再生。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
  申请人：Incyte Corporation

  公开号：EP2343298A1

  公开（公告）日：2011-07-13

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines (I) and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂芳基取代的吡咯并[2,3-b]吡啶(I)和杂芳基取代的吡咯并[2,3-b]嘧啶，它们能调节 Janus 激酶的活性，可用于治疗与 Janus 激酶活性有关的疾病，例如包括免疫相关疾病、皮肤病、骨髓增生性疾病、癌症和其他疾病。
• EP2776430B1
  申请人：——

  公开号：EP2776430B1

  公开（公告）日：2016-03-16